Journal article

Adjunctive aripiprazole for antipsychotic-related hyperprolactinaemia in patients with first-episode schizophrenia: a meta-analysis

Wei Zheng, Dong-Bin Cai, Xin-Hu Yang, Wei Zheng, Gabor S Ungvari, Chee H Ng, Zhan-Ming Shi, Mei-Ling Hu, Yu-Ping Ning, Yu-Tao Xiang

General Psychiatry | BMJ PUBLISHING GROUP | Published : 2019


Background: Hyperprolactinaemia is a common antipsychotic (AP)-induced adverse effect, particularly in female patients. Aims: This meta-analysis examined the efficacy and safety of adjunctive aripiprazole in preventing AP-related hyperprolactinaemia in patients with first-episode schizophrenia. Methods: PubMed, PsycINFO, EMBASE, Cochrane Library, WanFang and China Journal Net databases were searched to identify eligible randomised controlled trials (RCTs). Primary outcomes were the reductions of serum prolactin level and prolactin-related symptoms. Data were independently extracted by two reviewers and analysed using RevMan (V.5.3). Weighted/standardised mean differences (WMDs/SMDs)±95% CIs ..

View full abstract

University of Melbourne Researchers